MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Who May Qualify: 1. Written willing to sign a consent form must be signed before implementing any enrollment-related procedures; 2. Age ≥18 years old; 3. Patients with diagnosed by tissue sample (biopsy-confirmed) stage IIA-IIIC NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer, 8th Edition TNM staging)； 4. There is no special restriction on the source of genetic test report. 5. According to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), there is at least one radiographically measurable lesion. 6. Have not received any previous systemic antitumor therapy for advanced diseases. 7. No serious abnormalities of hematopoietic function, heart, lung, liver, kidney function and immune system. 8. ECOG score: 0-1; 9. Expected survival time \> 3 months. Who Should NOT Join This Trial: 1. Received surgical treatment for lung tumors. 2. Received neoadjuvant chemotherapy or radiotherapy. 3. Received cellular therapy within the last 1 year. 4. Treated but uncontrolled diabetes, mellitus, asthma, autoimmune conditions (where your immune system attacks your own body)s and other chronic diseases. 5. Participated in other clinical trials (including research vaccines, drugs, medical devices, etc.) within one month. Always talk to your doctor about whether this trial is right for you.